O’Melveny Represents OrbusNeich Medical Group in US$62 Million Hong Kong IPO
December 23, 2022
FOR IMMEDIATE RELEASE
HONG KONG, DECEMBER 23, 2022 — O’Melveny recently represented OrbusNeich Medical Group Holdings Limited (6929.HK) in its approximate US$61.6 million (approximately HK$481 million) initial public offering and listing of ordinary shares on the Main Board of the Hong Kong Stock Exchange. O’Melveny advised the company as to Hong Kong and U.S. laws.
Headquartered in Hong Kong, OrbusNeich is a global medical device manufacture specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. The company owns more than 180 granted patents globally across key jurisdictions, including 31 in the U.S. and 56 in the PRC. The company is among the top six players in PCI balloon markets in terms of sales volume in multiple countries including China, Japan, the U.S., and Europe.
China International Capital Corporation Hong Kong Securities Limited and CCB International Capital Limited are the Joint Sponsors, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers of the listing. The O’Melveny team also represented OrbusNeich in its over US$200 million Series A and A-2 financing rounds completed last year.
The O’Melveny team was led by corporate partners Edwin Kwok and Vincent Lin, and included counsel Wendy Kan, associates Wuxiao Liang, Amy Sung, trainee solicitors Cheryl Wong and Jeffrey Hang, and legal consultant Nick Mu.
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com, hear what our lawyers, staff and clients have to say in Our DNA video series, or learn more in our firm at-a-glance, annual report, and on LinkedIn, Twitter, Facebook, Instagram, and YouTube.
O’Melveny & Myers LLP
+1 212 326 2218
O’Melveny & Myers LLP
+86 21 2307 7000